Background: Management of resected gallbladder cancer relies on single-arm trials and retrospective observations. Our objective was to evaluate adjuvant therapy in a nationwide data set using causal inference methods to address sources of bias. Methods: We studied patients with T2-3 or node-positive, nonmetastatic gallbladder cancer, resected with grossly negative margins and reported to the National Cancer Data Base between 2004 and 2011. We defined adjuvant therapy as any chemotherapy within 90 days of surgery, and upfront concurrent chemoradiation as radiation within 14 days of first chemotherapy. After adjusting for missing data and guarantee-time bias, and using propensity score analysis to minimize indication bias, we compared overall survival of patients receiving adjuvant therapies with untreated case subjects. Results: Adjuvant chemotherapy was administered to 28.8% of 4775 patients, and upfront chemoradiation to 13.5%. Treatment was less frequent among patients who were older, patients with comorbidities, and among white Hispanic women. T3 or node-positive disease, microscopically positive margins, or extended resection increased the likelihood of adjuvant therapy. Overall survival at three years was 39.9% (95% confidence interval [CI] ¼ 38.4% to 41.4%) and was unaffected by adjuvant therapy after adjusting for multiple confounders (hazard ratio ¼ 1.01, 95% CI ¼ 0.92 to 1.10). Patients with T3 or node-positive tumors treated with upfront adjuvant chemoradiation had a modest early survival advantage (absolute difference at two years ¼ 6.8%, 95% CI ¼ 1.1% to 12.6%), but survival curves converged after five years of follow-up. Conclusions: The curative potential of current adjuvant therapy in gallbladder cancer is questionable, justifying placebocontrolled investigation of novel chemotherapy combinations or alternative approaches. Chemoradiation may provide a short-term benefit in locally advanced tumors.
Methods

Data Source and Cohort Selection
The study used de-identified data from the National Cancer Data Base (NCDB), a joint program of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. It was exempt from oversight of the local institutional review board. The NCDB is a nationwide oncology outcomes database sourced from over 1500 facilities, capturing up to 83% of newly diagnosed GBCA cases (8) . Participating institutions submit data on patient and tumor characteristics, first course of treatment, and survival, with mandatory 90% followup within five years from diagnosis. Treatments administered at recurrence are not recorded. We selected all patients with resected GBCA reported in 2004-2011, excluding noncarcinomas, T1N0, T4, M1, or unstaged cancers, patients for whom all treatment decisions were made outside of the reporting facility, or those with less than four months of follow-up after surgery ( Figure 1) . We also excluded patients with grossly positive surgical margins, debulking surgery only, medical contraindications to or missing data on chemotherapy, and those treated with preoperative chemotherapy.
Variables
Patients' race/ethnicity was classified as white non-Hispanic, white Hispanic, black, or other. Charlson-Deyo comorbidity index, which predicts the risk of death, was calculated from hospital records (9) . Socioeconomic status was available as median income in patient's area of residence according to the 2012 American Community Survey. Stage was assigned according to the American Joint Committee on Cancer (AJCC) tumor-nodemetastasis (TNM) systems-6th edition for 2004-2009 and 7th edition for 2010-2012. We harmonized those nonoverlapping systems by classifying tumors into three consistent categories: T2 N0/X, T3 N0/X, and node-positive (T1-3 N1-2) (10). N1/N2 categories were not distinguished prior to 2010.
We extracted data on surgery, chemotherapy, and radiation therapy administered as part of the initial course of treatment. We analyzed the extent of cholecystectomy (classified as simple/partial, "total," or "radical with adjacent organ resection"), performance of regional lymphadenectomy, additional resection of a distant node/site, presence of microscopically involved margins, lymphovascular invasion (LVI), tumor size greater than 5 cm, prolonged surgical stay, and unplanned readmission within 30 days.
We defined "adjuvant therapy" as chemotherapy (with or without radiation) initiated within 90 days of surgery. This definition captured 73.9% of all chemotherapy recipients while minimizing misclassification of palliative treatments for early recurrence. Upfront CRT was defined as radiation initiated within 614 days of the first chemotherapy. We could not include chemotherapy followed by CRT in this definition because there was no indication if later radiation was delivered concurrently with chemotherapy. Specific regimens, duration of, and response to treatment were not available. Overall survival (OS), calculated from the date of surgery and censored at last follow-up, was the primary endpoint. 
Statistical Analysis
We compared the distribution of baseline variables by chi-squared tests. In the comparative causal inference analysis, we addressed three major sources of potential bias: missing data, guaranteetime bias, and indication bias. Missing data on race/ethnicity (1.1%), health insurance (1.7%), income (3.2%), duration of surgical stay (13.7%), type of primary resection (2.6%), readmissions (3.4%), lymphadenectomy (0.4%), tumor size (33.8%), grade (5.9%), and LVI (77.8%) were handled using multiple imputation by chained equations, assuming that data were missing at random (11) . Imputation models included exposure (adjuvant therapy), outcome (cumulative hazard of death), and all covariates from the analytic models, generating 80 imputed data sets. Factors associated with adjuvant chemotherapy were analyzed in a multivariable robust Poisson model, which directly estimates relative risk (RR), averaging coefficients across imputations according to Rubin's rules (12) . Guarantee-time bias arises in comparative research when survival time is measured from enrollment (eg, diagnosis), but the classifying event (receipt of treatment) occurs during follow-up. This creates an apparent survival disadvantage for the untreated group, which automatically includes all patients who die prior to receiving therapy. We addressed guarantee-time bias by landmark analysis (one of the recommended corrective approaches), excluding patients with less than four months of follow-up (13) . Indication bias resulting from systematic differences in baseline characteristics between treated and untreated groups was minimized by propensity score analysis. We calculated the propensity score using a logistic regression model that included all available confounders, averaging coefficients over imputed data sets, and removing subjects with nonoverlapping propensity score values (14) . We generated balanced arms using two implementations of the propensity score methodology suitable for survival analysis: inverse probability of treatment weighting (IPTW) and greedy matching in a 1:1 ratio (with a caliper equal to 0.2*standard deviation of the propensity score logit) (15) . IPTW provides an estimate of the "average treatment effect" (marginal effect for the entire cohort), whereas matching provides the "average treatment effect in the treated" (marginal effect for recipients of therapy) (16) . Balance of confounders was confirmed by standardized difference of means, conventionally required to reach less than 10%. OS curves were generated from Kaplan-Meier estimators in the IPTWadjusted sample (17) . When the proportional hazard assumption (assessed by Grambsch-Therneau test of Schoenfeld residuals) was met, we expressed treatment effect as marginal hazard ratio (HR) in a univariate Cox model. Otherwise, we expressed treatment effect as a difference in restricted mean survival time (RMST) at five years of follow-up (using the strmst2 module by Angel Cronin, 2016, http://ideas.repec.org/c/boc/bocode/s458154. html) (18) . We explored the heterogeneity of treatment effects by interacting treatment indicators with variables of interest in the Cox model. Finally, we performed a sensitivity analysis for unobserved confounding by simulating a putative risk factor unevenly distributed between treatment arms (19) . All analyses were conducted using Stata/MP 14.1 (StataCorp LP, College Station, TX), reporting 95% confidence intervals (CIs), with two-sided alpha levels of less than .05 considered statistically significant.
Results
Patient Characteristics
The characteristics of all resected GBCA patients (n ¼ 8543) are listed in Supplementary Cholecystectomy was "simple/partial" in 20.8%, "total" in 67.2%, and "radical with adjacent organ resection" in 9.1%. Among patients treated in 2010 and 2011 whose surgical approach was recorded (n ¼ 2077), 42.4% underwent open resection, 45.6% laparoscopy, and 12.0% laparoscopy converted to laparotomy.
Among the 4775 patients in the final analytic cohort, 1373 (28.8%) received adjuvant chemotherapy (Table 1) , including 646 (13.5%) who received upfront CRT (Supplementary Table 2 , available online). Chemotherapy was single-agent in 56.9%, multiagent in 33.4%, and unspecified in 9.7% of patients. We noted a higher proportion of patients receiving multi-agent regimens in 2010 and 2011 (42.7%) than in 2004-2009 (29.0%, P < .001). The proportion receiving chemotherapy was 16.6% for T2, 34.4% for T3, and 43.8% for node-positive GBCA, whereas for upfront CRT these proportions were 8.9%, 15.0%, and 19.8%, respectively. Among patients receiving upfront adjuvant chemotherapy alone, 247 (34.3%) received radiation therapy later on. Median time from surgery to chemotherapy was 59 days (IQR ¼ 41-85 days). For the CRT group, median total radiation dose was 50.4 Gy (IQR ¼ 45-54 Gy).
In a multivariable model (Table 2) , adjuvant therapy was statistically significantly less likely among patients older than age 70 years, those with comorbidities, and those with Medicaid insurance (a correlate of poverty or disability). White Hispanic women had a lower rate of adjuvant therapy compared with other subgroups. Adjuvant treatment was also more common among patients with more advanced or larger tumors, those with microscopically positive margins, or after a radical resection. There was no statistically significant difference between academic and community centers.
Survival Outcomes
Median follow-up time for censored patients was 3.1 years (IQR ¼ 1.7-5.0 years). Median OS for all patients who underwent resection was 1.7 years (95% CI ¼ 1.7 to 1.8 years), and three-year OS was 36.7% (95% CI ¼ 35.6% to 37.8%). This was 59.4% (95% CI ¼ 56.5% to 61.2%) for T1N, 45.1% (95% CI ¼ 43.2% to 47.0%) for T2, 18.2% (95% CI ¼ 16.3% to 20.1%) for T3, and 26.4% (95% CI ¼ 24.4% to 28.4%) for node-positive tumors. OS was better among patients undergoing radical cholecystectomy and regional lymphadenectomy (Supplementary Figure 1 , available online).
We compared OS of patients in the main analytic cohort (n ¼ 4775) according to receipt of adjuvant therapy. In this group, three-year OS was 39.9% (95% CI ¼ 38.4% to 41.4%), or 51.3% (95% CI ¼ 49.1% to 53.5%), 26.1% (95% CI ¼ 23.2% to 29.1%), and 31.4% (95% CI ¼ 28.9% to 34.0%) for T2, T3, and node-positive tumors, respectively. In the IPTW-adjusted analysis (n ¼ 4708, after removing 67 subjects with nonoverlapping propensity score values), the comparative arms were adequately balanced with regard to all available confounders (Figure 2A ). We found no difference in OS between the groups (HR ¼ 1.01, 95% CI ¼ 0.92 to 1.10, P ¼ .91) ( Figure 2B ) and no evidence of heterogeneity across subsets defined by propensity score quintiles (P interaction ¼ .14), age (P ¼ .66), stage (P ¼ .32), extent of surgery (P ¼ .39), margin status (P ¼ .70), performance of lymphadenectomy (P ¼ .07), or single/multi-agent chemotherapy (P ¼ .94) ( Supplementary  Figure 2 , available online). Sensitivity analysis indicated that a 
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putative unobserved confounder would need to have 30% or more higher prevalence in the treated group for the hazard ratio to become statistically significant in favor of adjuvant therapy ( Figure 2C ). The results were consistent in the 1:1 matching implementation, in which 1203 treated patients (87.6%) were matched to untreated control subjects with a hazard ratio of 1. We additionally conducted an analysis of adjuvant upfront CRT (vs no therapy) among patients with T3 or node-positive cancers (n ¼ 1924). After adequately balancing confounders between the arms (data not shown), median OS in the IPTWadjusted analysis was modestly prolonged, but survival curves converged after five years of follow-up (Figure 3 ), resulting in a nonproportional hazard. The difference in RMST (within the time horizon of five years) was statistically significant (0.25 years, 95% CI ¼ 0.06 to 0.44 years, P ¼ .009). The interpretation of this value is that, among patients followed for up to five years, those who received adjuvant upfront CRT lived on average three months longer compared with those who did not get any adjuvant therapy. The maximum OS difference between the groups was 6.8% at two years (95% CI ¼ 1.1% to 12.6%). Similarly, in a matched analysis with 417 case subjects (94.3%) matched to control subjects, the RMST difference was 0.27 years (95% CI ¼ 0.03 to 0.52 years, P ¼ .03), but the survival curves also converged after five years of follow-up.
Discussion
In this analysis using comprehensive registry data that included most patients with T2-3 or node-positive GBCA in the United States between 2004 and 2011, we used causal inference methods to evaluate adjuvant therapy as currently applied in routine practice. We found that only 28.8% of potentially eligible patients received adjuvant therapy within three months of surgery, with no evidence of a survival advantage overall and only a modest, short-term benefit from upfront concurrent CRT in the subgroup with T3 or node-positive tumors.
GBCA is characterized by high rates of local and distant spread, and its prognosis is worse than in extrahepatic cholangiocarcinoma, thus weakening the validity of data extrapolations (20) . Only limited prospective evidence supports adjuvant therapy in GBCA (3, 4) . In one trial enrolling various pancreatobiliary malignancies in 1986-1992, 112 GBCA subjects were randomly assigned to adjuvant chemotherapy (mitomycin and 5-fluorouracil) or observation. Five-year OS was better after chemotherapy (26.0%) compared with observation (14.4%) in the per-protocol, but not in the intent-to-treat analysis (1). Of note, 30% of control subjects were excluded, and the survival advantage was only present in a subgroup undergoing noncurative surgery, without any evident advantage after a complete resection. In a phase 2 Southwest Oncology Group trial (SWOG-0809), 54 patients with extrahepatic cholangiocarcinoma and 25 with radically resected GBCA received four cycles of adjuvant gemcitabine and capecitabine, followed by CRT (21) . Despite an optimistic two-year OS of 65%, the interpretation of this trial is limited by its nonrandomized design, short follow-up, and low number of subjects with GBCA (22) . In our analysis, despite the statistically significant advantage of adjuvant CRT at two years, survival curves converged with longer follow-up. Moreover, most patients in the community undergo nonradical, potentially suboptimal resections, which would have excluded them from SWOG-0809. Expert consensus recommends en bloc adjacent liver resection for all operable tumors stage T1b or higher with regional lymphadenectomy (6). Our negative finding may thus result from prevalent suboptimal surgical practice. Although we did not detect a statistically significant interaction between adjuvant therapy and extent of resection, only a minority of patients underwent radical cholecystectomies, lowering the statistical power. Efforts to improve outcomes in GBCA should thus focus on standardizing the surgical technique, and adjuvant therapy would be best studied in the context of optimal resection.
Evidence supporting adjuvant therapy in GBCA largely relies on retrospective studies. This was summarized by a metaanalysis of 20 observational series involving 6712 patients with resected biliary tract cancers, which reported a statistically nonsignificant improvement in five-year OS after adjuvant therapy over surgery alone (odds ratio [OR] ¼ 0.74, P ¼ .06) (23) . A subgroup analysis suggested a benefit in node-positive or R1 disease (OR ¼ 0.49 and 0.36, respectively), but the conclusion advocating adjuvant therapy has been criticized (4). Data were pooled almost exclusively from retrospective studies subject to many, largely unaddressed, forms of bias. Diverse pancreatobiliary cancers were included, and the benefit in GBCA was only evident after exclusion of registry studies, leaving singleinstitution series characterized by inherent selection and ARTICLE indication bias (24) . This clinical selection is evident in our data set as older, sicker, or disabled patients were less likely to receive therapy. Moreover, most studies were undermined by a gross guarantee-time bias leading to overestimation of benefit (13) . Despite efforts in educating researchers about guaranteetime bias, it remains a serious deficiency in many observational studies of cancer therapy (25) . Additional issues include short follow-up and a publication bias against reports showing no benefit. We attempted to overcome several of those shortcomings using causal inference methods and leveraging the extensive set of patient-, surgery-, and tumor-related variables available in the NCDB. Additionally, our sensitivity analysis suggested that further unobserved confounding would have to be large to obscure a clinically significant advantage of therapy. We observed that patients with T3 and node-positive GBCA who received adjuvant upfront CRT within three months of surgery had modestly improved OS at two years. This benefit was not evident with longer follow-up, indicating that CRT may principally delay cancer recurrence. We note that patients receiving CRT after initial chemotherapy were not included in this comparison, so our study did not address potential benefits of such sequential approach (as in SWOG-0809). This option is still not explicitly included in the NCCN guidelines and cannot be reliably discerned from the NCDB data. Some retrospective reports suggested a benefit of adjuvant CRT in T2-3 or nodepositive disease, but most were small and highly biased (26, 27) . A registry-based analysis of 1137 Medicare beneficiaries treated in 1995-2005 predicted a variable benefit from CRT from a nomogram (28) . However, the nomogram omitted too many critical confounders (including patients' baseline health, type and extent of surgery, margins, tumor grade) to adequately address the indication bias and estimate treatment effect (29, 30) . In addition, radiation and chemotherapy were allowed at any time within six months of surgery, resulting in a guarantee-time bias in favor of the treated group. In contrast, we considered CRT only when both modalities started concurrently and within three months of resection. Both studies suffer from inability to ascertain chemotherapy drugs and doses, duration of treatment, or its actual adjuvant intent.
In most historical analyses discussed above, as likely in our cohort, adjuvant chemotherapy involved single-agent fluoropyrimidine or gemcitabine. However, monotherapy may not be sufficient to eradicate residual disease in an aggressive malignancy like GBCA. The doublet of cisplatin-gemcitabine is a superior regimen for advanced or metastatic biliary cancers (31) . Ongoing studies are evaluating adjuvant gemcitabine with cisplatin (NCT02170090, NCT01073839, NCT01297998) or oxaliplatin (NCT01313377). Trials should further exploit shared genomic alterations and genetic signatures to identify subgroups that could benefit from specific chemotherapeutic or targeted agents (5, 32, 33) .
Our study has several limitations related to its design and data source. We could only study OS using the NCDB, but other endpoints, like disease-free survival, are important in the curative setting, particularly for patients who are older or who have comorbidities as they experience higher mortality from competing, noncancer causes. Patients selected for adjuvant treatment may have high-risk characteristics difficult to capture even in the comprehensive NCDB data. Such confounding would conceal any potential advantage of therapy. For example, specific data on resection of the biliary tree or liver and on patients' performance status were unrecorded. Clinicians' assessment of postoperative clinical fitness and overall prognosis may also affect treatment decisions, and the propensity score methodology ARTICLE used in our analysis relies explicitly on the assumption of no unobserved confounding. Alternative methods, such as instrumental variable analysis, also involve complex assumptions, and their application to survival analysis remains controversial (34) . In some cases, palliative chemotherapy for early recurrence may have been misclassified as adjuvant. Lastly, we excluded about 25% of patients because of insufficient follow-up, thus narrowing the applicable population.
In conclusion, our results support the NCCN-endorsed consideration of adjuvant concurrent CRT in patients with T3 or node-positive GBCA, but put into question survival benefits of adjuvant chemotherapy as practiced in the US community. While this may be disconcerting, we believe that prior retrospective data claiming survival advantage were biased, and our study provides a more realistic assessment. Adjuvant trials using placebo or concurrent CRT as control arms are justified and should report outcomes beyond two to three years of follow-up to evaluate a true curative potential. Clinicians should discuss the uncertain benefit and potential risks of adjuvant therapy when counseling their patients and encourage enrollment in clinical trials of novel regimens. Improving surgical technique to align the prevalent practice with expert guidelines might help to improve the persistently poor outcomes in GBCA. Future research should evaluate more active, multi-agent regimens, or targeted agents, in a more homogenous population of GBCA patients.
Funding
The study was conducted using institutional funds.
Notes
The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.
The authors declare no conflicts of interest. Overall survival curves after adjustment by inverse probability of treatment weighting (n ¼ 4708); P value was calculated from the two-sided Wald test. C) Sensitivity analysis for unobserved confounding: Numbers in squares show corrected hazard ratios (HRs) for adjuvant chemotherapy in a hypothetical scenario where an unobserved confounder (associated with an HR of 1.5) is present with a specified prevalence in each treatment arm. Shaded background indicates scenarios in which hazard ratio for adjuvant chemotherapy would become statistically significant. CI ¼ confidence interval. 
